Literature DB >> 31602385

Endoscopic Upper GI Screening.

Alanna Ebigbo1, Helmut Messmann1, Christoph Römmele1.   

Abstract

The rationale behind endoscopic screening of the upper gastrointestinal tract (GIT) in the West is different from Asian countries with a high prevalence of gastric cancer. If epidemiological data on upper GIT cancer in the Western world is considered, then endoscopic screening of the upper GIT must target premalignant conditions as well and, furthermore, lay emphasis on the assessment of the entire upper GIT in high-risk individuals from the mouth till the duodenum. Although data on the incidence, prevalence, and further development of premalignant conditions in the upper GIT is lacking, a risk-based approach to endoscopic screening will be more cost-effective than a general screening approach. Finally, endoscopists need to be educated and trained in the assessment of the upper GIT during screening endoscopy.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Cancer; Endoscopy; Screening

Year:  2019        PMID: 31602385      PMCID: PMC6738244          DOI: 10.1159/000501889

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  17 in total

Review 1.  Screening of gastric cancer in Asia.

Authors:  Kentaro Sugano
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-09-25       Impact factor: 3.043

2.  Overview of esophageal cancer.

Authors:  Ghulam Abbas; Mark Krasna
Journal:  Ann Cardiothorac Surg       Date:  2017-03

3.  An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013.

Authors:  Kota Katanoda; Megumi Hori; Tomohiro Matsuda; Akiko Shibata; Yoshikazu Nishino; Masakazu Hattori; Midori Soda; Akiko Ioka; Tomotaka Sobue; Hiroshi Nishimoto
Journal:  Jpn J Clin Oncol       Date:  2015-01-30       Impact factor: 3.019

Review 4.  Precancerous lesions in the stomach: from biology to clinical patient management.

Authors:  Massimo Rugge; Lisette G Capelle; Rocco Cappellesso; Donato Nitti; Ernst J Kuipers
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-04       Impact factor: 3.043

5.  Divergent trends for gastric cancer incidence by anatomical subsite in US adults.

Authors:  M Constanza Camargo; William F Anderson; Jessica B King; Pelayo Correa; Cheryll C Thomas; Philip S Rosenberg; Christie R Eheman; Charles S Rabkin
Journal:  Gut       Date:  2011-05-25       Impact factor: 23.059

6.  Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019.

Authors:  Pedro Pimentel-Nunes; Diogo Libânio; Ricardo Marcos-Pinto; Miguel Areia; Marcis Leja; Gianluca Esposito; Monica Garrido; Ilze Kikuste; Francis Megraud; Tamara Matysiak-Budnik; Bruno Annibale; Jean-Marc Dumonceau; Rita Barros; Jean-François Fléjou; Fátima Carneiro; Jeanin E van Hooft; Ernst J Kuipers; Mario Dinis-Ribeiro
Journal:  Endoscopy       Date:  2019-03-06       Impact factor: 10.093

7.  Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development.

Authors:  Su Youn Nam; Bum Joon Park; Ji Hyung Nam; Myeong-Cherl Kook
Journal:  Gastrointest Endosc       Date:  2019-04-26       Impact factor: 9.427

8.  Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age.

Authors:  Linda Morris Brown; Susan S Devesa; Wong-Ho Chow
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

Review 9.  Screening and surveillance for gastric cancer in the United States: Is it needed?

Authors:  Gwang Ha Kim; Peter S Liang; Sung Jo Bang; Joo Ha Hwang
Journal:  Gastrointest Endosc       Date:  2016-03-03       Impact factor: 9.427

10.  Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012.

Authors:  Kyu-Won Jung; Young-Joo Won; Hyun-Joo Kong; Chang-Mo Oh; Hyunsoon Cho; Duk Hyoung Lee; Kang Hyun Lee
Journal:  Cancer Res Treat       Date:  2015-03-03       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.